Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 3/20 | 0.57 |
| ▸ | ATP4B known ✓ | P51164 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | WDR5 | P61964 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.57 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL1457174 | 1.00 | CYP2C9 (0.59) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1457598 | 0.99 | CYP2C9 (0.58) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL4785971 | 0.99 | CYP2C9 (0.58) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL1457599 | 0.99 | CYP2C9 (0.58) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL14482090 | 0.96 | CYP2C9 (0.59) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1457400 | 0.96 | NPC1 (0.61) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL1457401 | 0.96 | NPC1 (0.61) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 0.96 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 0.96 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 0.96 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077866-A1 | PROCESS FOR MANUFACTURING MICROCRYSTALLINE LANSOPRAZOLE FORM I | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2008-07-03 | — | — | WO | claimed |
| EP-2573082-A1 | CRYSTALLINE SOLVATED FORMS OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE | Takeda Pharmaceutical Company Limited (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2292612-A2 | Crystalline solvated forms of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole | Takeda Pharmaceutical Company Limited (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100286400-A1 | CRYSTALLINE SOLVATED FORMS OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| WO-2008077866-A1 | PROCESS FOR MANUFACTURING MICROCRYSTALLINE LANSOPRAZOLE FORM I | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2008-07-03 | — | — | WO | disclosed |